Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy And Safety of BXCL501 Evaluated For At-Home Use In A Multisite Double-Blind Placebo-Controlled Trial For Agitation Associated With Schizophrenia And Bipolar Disorder

NCT05658510 is registered in ClinicalTrials.gov with BioXcel Therapeutics Inc as lead sponsor.

NCT NCT05658510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05658510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy And Safety of BXCL501 Evaluated For At-Home Use In A Multisite Double-Blind Placebo-Controlled Trial For Agitation Associated With Schizophrenia And Bipolar Disorder
Lead sponsor
BioXcel Therapeutics Inc
Phase
Phase 3
Overall status
Completed
Start date
November 21, 2022
Completion date
August 15, 2025
Enrollment
452 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

agitation,psychomotor, bipolar i disorder, bipolar ii disorder, schizoaffective disorder, schizophrenia, schizophreniform disorders